1. Usability and robustness of the Wixela Inhub dry powder inhaler;Allan;J. Aerosol Med. Pulm. Drug Del.,2020
2. FDA recommendations for the design and implementation of in vitro and in vivo alternative bioequivalence approaches;Bielski;Respir. Drug Deliv.,2024
3. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline;Borgstrom;Pharm. Res.,1990
4. Methods to identify drug deposition in the lungs following inhalation;Chrystyn;Br. J. Clin. Pharmacol.,2001
5. BCS Biowaivers: similarities and differences among EMA, FDA, and WHO requirements;Davit;AAPS J,2016